Ionis Pharmaceuticals (IONS) Interest Expenses (2009 - 2026)

Ionis Pharmaceuticals' Interest Expenses history runs 18 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 25.61% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $18.3 million (up 8.05% YoY), while the FY2025 annual figure was $17.3 million, up 1.58% from the prior year.
• Interest Expenses was $5.2 million for Q1 2026 at Ionis Pharmaceuticals, up from $4.8 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $5.2 million in Q1 2026 to a low of $1.6 million in Q1 2023.
• Historically, Interest Expenses has averaged $3.5 million across 5 years, with a median of $4.2 million in 2024.
• Biggest YoY gain for Interest Expenses was 163.32% in 2023; the steepest drop was 24.22% in 2023.
• A 5-year view of Interest Expenses shows it stood at $1.7 million in 2022, then soared by 163.32% to $4.6 million in 2023, then dropped by 8.05% to $4.2 million in 2024, then gained by 15.2% to $4.8 million in 2025, then increased by 6.88% to $5.2 million in 2026.
• The last three Interest Expenses figures came in at $5.2 million (Q1 2026), $4.8 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.